Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Here's Where Wall Street Analysts See Eli Lilly's Share Price Going

2026-09-26 16:32 • The Motley Fool Positive Axe Cap view: Selective

Eli Lilly's stock has underperformed the broader market in 2026 despite a strong 5-year run, trading at 40x earnings. Wall Street analysts are modestly bullish with an average price target of $1,325 (11% upside), with 25 of 30 analysts recommending buy. The expanding GLP-1 market, projected to reach $190 billion by 2045, and Lilly's strong patent protection through the late 2030s support a positive outlook despite competitive threats from Novo Nordisk.

Axe note: Strong GLP-1 drug sales power Eli Lilly but USD/ZAR dynamics temper enthusiasm.

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

2026-09-26 16:15 • The Motley Fool Positive Axe Cap view: Selective

Eli Lilly discontinued development of a new GLP-1 weight-loss drug that failed to meet efficacy expectations. While GLP-1 drugs (Mounjaro, Zepbound, Foundayo) account for over 65% of the company's revenue, Eli Lilly is strategically preparing for future patent expirations by aggressively investing in its drug pipeline through acquisitions and in-house research, particularly in infectious diseases. The company's willingness to cut underperforming candidates and move quickly on acquisitions demonstrates strong long-term strategic positioning.

Axe note: Dropping a weight-loss drug shows Lilly’s focus on quality and long-term positioning beyond GLP-1 revenues.

The 3 "Magnificent Seven" Stocks That I'm Buying Now

2026-09-26 15:30 • The Motley Fool Positive Axe Cap view: Selective

The author recommends three Magnificent Seven stocks as the best buys: Nvidia, Alphabet, and Amazon. Nvidia is highlighted as undervalued despite its $5.4 trillion market cap, with potential to double by early 2028 based on expected 70% revenue growth driven by AI data center spending. Alphabet and Amazon are positioned to benefit from their leading cloud computing platforms (Google Cloud and AWS), with significant capital expenditures in 2027 expected to drive recurring revenue streams from AI clients.

Axe note: Nvidia, Alphabet, and Amazon stand out in AI-led cloud growth with clear growth narratives and valuation potential.

See all market stories →

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand